Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas J Moore

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
BMJ Open|April 24, 2023
Medical use and combination drug therapy among US adult users of central nervous system stimulants: a cross-sectional analysisThomas J Moore, Phillip W Wirtz, Jill N Curran, et al.
The Journal of Hand Surgery|March 5, 2011
Compartment syndrome of the upper extremityFraser J Leversedge, Thomas J Moore, Bret C Peterson, et al.
Pharmacoepidemiology and Drug Safety|February 11, 2016
Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014Thomas J Moore, Curt D Furberg, Donald R Mattison, et al.
Neurology|December 30, 2021
Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson DiseaseY Joseph Hwang, G Caleb Alexander, Thomas J Moore, et al.
BMJ Open|August 14, 2021
Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional studyThomas J Moore, Phillip W Wirtz, Stefan P Kruszewski, et al.
Archives of Physiotherapy|January 18, 2018
Can experienced physiotherapists identify which patients are likely to succeed with physical therapy treatment?Chad E Cook, Thomas J Moore, Kenneth Learman, et al.
Plos One|November 11, 2011
Suicidal behavior and depression in smoking cessation treatmentsThomas J Moore, Curt D Furberg, Joseph Glenmullen, et al.
Therapeutic Innovation & Regulatory Science|February 11, 2026
Deficiencies Delaying Prescription Drug Approvals by the U.S. Food and Drug Administration, 2020-2024Sophie Dilek, Richard H Woods, Jeromie Ballreich, et al.
Annals of Internal Medicine|September 28, 2020
Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018James Heyward, Thomas J Moore, Jennifer Chen, et al.
BMJ Open|June 11, 2020
Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysisHemalkumar B Mehta, Stephan Ehrhardt, Thomas J Moore, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
BMJ Open|April 24, 2023
Medical use and combination drug therapy among US adult users of central nervous system stimulants: a cross-sectional analysisThomas J Moore, Phillip W Wirtz, Jill N Curran, et al.
The Journal of Hand Surgery|March 5, 2011
Compartment syndrome of the upper extremityFraser J Leversedge, Thomas J Moore, Bret C Peterson, et al.
Pharmacoepidemiology and Drug Safety|February 11, 2016
Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014Thomas J Moore, Curt D Furberg, Donald R Mattison, et al.
Neurology|December 30, 2021
Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson DiseaseY Joseph Hwang, G Caleb Alexander, Thomas J Moore, et al.
BMJ Open|August 14, 2021
Changes in medical use of central nervous system stimulants among US adults, 2013 and 2018: a cross-sectional studyThomas J Moore, Phillip W Wirtz, Stefan P Kruszewski, et al.
Archives of Physiotherapy|January 18, 2018
Can experienced physiotherapists identify which patients are likely to succeed with physical therapy treatment?Chad E Cook, Thomas J Moore, Kenneth Learman, et al.
Plos One|November 11, 2011
Suicidal behavior and depression in smoking cessation treatmentsThomas J Moore, Curt D Furberg, Joseph Glenmullen, et al.
Therapeutic Innovation & Regulatory Science|February 11, 2026
Deficiencies Delaying Prescription Drug Approvals by the U.S. Food and Drug Administration, 2020-2024Sophie Dilek, Richard H Woods, Jeromie Ballreich, et al.
Annals of Internal Medicine|September 28, 2020
Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018James Heyward, Thomas J Moore, Jennifer Chen, et al.
BMJ Open|June 11, 2020
Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysisHemalkumar B Mehta, Stephan Ehrhardt, Thomas J Moore, et al.
Pageof 8